-
Company Insights
Innovation and Patenting activity of Neuren Pharmaceuticals Ltd Q4 2023
GlobalData, the industry analysis specialist, has released its latest company patent databook "Innovation and Patenting activity of Neuren Pharmaceuticals Ltd Q4 2023". The databook highlights patenting activity of the company in terms of growth in filings and grants, regions protected, impact of various themes, sector applicability of technologies protected. It provides contextual analysis of technical peers, their strategy, dominance (Grant share) and their recent activities. This is an on-demand databook that will be delivered upon request. The report will be...
-
Product Insights
Likelihood of Approval and Phase Transition Success Rate Model – ACP-2591 in Prader-Willi Syndrome (PWS)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - ACP-2591 in Prader-Willi Syndrome (PWS) report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. ACP-2591 in Prader-Willi Syndrome (PWS) Drug Details: NNZ-2591 is under development...
-
Product Insights
Likelihood of Approval and Phase Transition Success Rate Model – ACP-2591 in Rett Syndrome
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - ACP-2591 in Rett Syndrome report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. ACP-2591 in Rett Syndrome Drug Details: NNZ-2591 is under development for the...
-
Product Insights
Likelihood of Approval and Phase Transition Success Rate Model – ACP-2591 in Angelman Syndrome
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - ACP-2591 in Angelman Syndrome report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. ACP-2591 in Angelman Syndrome Drug Details: NNZ-2591 is under development for the...
-
Product Insights
Likelihood of Approval and Phase Transition Success Rate Model – ACP-2591 in Phelan-McDermid Syndrome (22q13.3 Deletion Syndrome)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - ACP-2591 in Phelan-McDermid Syndrome (22q13.3 Deletion Syndrome) report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. ACP-2591 in Phelan-McDermid Syndrome (22q13.3 Deletion Syndrome) Drug Details:...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – AMG-305 in Malignant Mesothelioma
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - AMG-305 in Malignant Mesothelioma report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. AMG-305 in Malignant Mesothelioma Drug Details: Monoclonal antibody is under development...
-
Product Insights
NewFragile X Syndrome Clinical Trial Analysis by Phase, Trial Status, End Point, Sponsor Type and Region, 2024 Update
Fragile X Syndrome Clinical Trial Report Overview A total of 110 fragile X syndrome clinical trials were conducted as of March 2024. The fragile X syndrome clinical trial report provides a comprehensive understanding of the fragile X syndrome clinical trial scenario across regions, and countries (G7 & E7), along with insights into the various phases, trial status, and end points status. The report also includes information about the sponsor types and the prominent sponsors associated with the trials. Key Regions...
-
Product Insights
Angelman Syndrome – Drugs In Development, 2023
Global Markets Direct’s, ‘Angelman Syndrome - Drugs In Development, 2023’, provides an overview of the Angelman Syndrome pipeline landscape. The report provides comprehensive information on the therapeutics under development for Angelman Syndrome, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an...
-
Product Insights
Phelan-McDermid Syndrome (22q13.3 Deletion Syndrome) – Drugs In Development, 2023
Global Markets Direct’s, ‘Phelan-McDermid Syndrome (22q13.3 Deletion Syndrome) - Drugs In Development, 2023’, provides an overview of the Phelan-McDermid Syndrome (22q13.3 Deletion Syndrome) pipeline landscape. The report provides comprehensive information on the therapeutics under development for Phelan-McDermid Syndrome (22q13.3 Deletion Syndrome), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest...
-
Product Insights
Rett Syndrome – Drugs In Development, 2023
Global Markets Direct’s, ‘Rett Syndrome - Drugs In Development, 2023’, provides an overview of the Rett Syndrome pipeline landscape. The report provides comprehensive information on the therapeutics under development for Rett Syndrome, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an...